AzTrials
AzTrials

Kidney Failure, Chronic3SNCT02453412

Preoperative Arteriovenous Fistula Simulation Study (ShuntSimulationStudy)

A study testing AVF-simulation in people with Kidney Failure, Chronic and Arteriovenous Fistulae, run by Maastricht University Medical Center at 9 sites in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients suffering from end-stage renal disease (ESRD) are dependent on renal replacement therapy (dialysis). The majority of dialysis is facilitated by hemodialysis. For hemodialysis a vascular access is necessary, preferable an arteriovenous fistula (AVF) in which a vein is directly anastomosed to an artery. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
AVF-simulation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
236 participants
Where
9 sitesNetherlands
Study dates
May 2015to Jun 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Incident patients that enter the pre-dialysis program because of end-stage renal failure and need for vascular access.
  • Permanent dialysis patients in need of a new VA in the contralateral arm because of a previous failed access.
  • Patients in which treatment of first choice is the creation of an autologous AVF.
  • Patients with adequate arteries and veins (duplex) for creation of RC-, BC- or BBAVF.
  • Patients that signed the written informed consent.

Who cannot join

  • Patients with contraindications for creation of an autologous AVF (skin infection, ischemia, heart failure)
  • Patients with a previous vascular access in the ipsilateral arm.

Trial locations and contacts

9 sites in 1 country.

9 sites in 1 country

Netherlands9 sites
  • Flevoziekenhuis

    Almere Stad, Flevoland, 1315RA

  • Slingeland ziekenhuis

    Doetinchem

  • Catharina ziekenhuis

    Eindhoven

  • Zuyderland

    Heerlen

  • Maastricht University Medical Center

    Maastricht, 6229HX

  • St. Antonius ziekenhuis

    Nieuwegein

  • Laurentius ziekenhuis

    Roermond

  • Maasstad Ziekenhuis

    Rotterdam, South Holland, 3079DZ

  • UMC Utrecht

    Utrecht

Other trials in Netherlands

About this study

Official title: Randomized-controlled Clinical Trial for the Evaluation of the Efficacy of Computational Simulation for the Planning of Vascular Access Surgery in Hemodialysis Patients

Patients suffering from end-stage renal disease (ESRD) are dependent on renal replacement therapy (dialysis). The majority of dialysis is facilitated by hemodialysis. For hemodialysis a vascular access is necessary, preferable an arteriovenous fistula (AVF) in which a vein is directly anastomosed to an artery. In order to use the AVF for hemodialysis three criteria have to be met; the minimal flow over the AVF is 600 mL/min, the diameter is at least 6 mm, and the AVF is located less than 6 mm under the skin. Unfortunately, approximately half of the patients (50%) are confronted with an AVF that does not meet these criteria; the so called non-maturation or primary failure. In case of non-maturation the AVF is not only unusable for dialysis, but also requires reinterventions on short- and long-term. Firstly to mature the AVF, and secondly, when the AVF is matured, to keep the vascular access. Using a computational simulation postoperative flow can be predicted. Based on patient-specific duplex measurements, the model can calculate the flow that can be expected following vascular access surgery for all AVF configurations; fore- or upper arm. These calculations lead to an advice which configuration is indicated; a flow that exceeds 600 mL/min, leading to maturation. Potentially the aforementioned 50% of non-maturation can be reduced. The patient then has an adequate vascular access and reinterventions are adverted, resulting in a decrease of costs, hospital demand, and an increase of the patients' quality of life. When the expected reduction of non-maturation is confirmed, the computational tool can be offered to other hospitals.

Read the detailed description

End-stage renal disease (ESRD) is a major and growing healthcare problem associated with substantial costs. By the end of 2010 the global patient population requiring chronic renal replacement therapy (RRT) exceeds 2 million, of which approximately 90% relies on hemodialysis (HD). The number of patients dependent on RRT are expected to annually increase with 8%. Based on this figure, it is expected that in 2030, 7.3 million ESRD patients need HD treatment. To facilitate adequate HD therapy a reliable vascular access (VA) is mandatory and can be provided by either creation of an autologous arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG) or a central venous catheter (CVC). Guidelines by the National Kidney Foundation (NKF K/DOQI Guidelines), the Vascular Access Society (Good Nephrological Practice Guidelines) and the European Dialysis and Transplant Association (European Best Practice Guidelines on vascular access) advocate the implementation of an all-autologous fistula policy to maximize the use of AVF over AVG and CVC because AVF have the best long-term patency, fewer complications and require less interventions once fully maturated. Although the implementation of preoperative ultrasonography examination for vessel assessment has reduced the number of early AVF failure by improving the selection of the most suitable vessels and site for AVF creation, short- and long-term AVF dysfunction remains the major cause of morbidity and hospitalisation in HD patients, and is therefore the major limitation for HD treatment. This dysfunction is usually associated with non-maturation of the newly created AVF or the formation of neo-intimal hyperplasia (NIH) which potentially results in decreased access flow and eventual fistula thrombosis in up to 50% of AVFs. On the other hand, the low resistance vascular traject via the AVF may lead to impeded perfusion of the extremity distally of the AV anastomosis resulting in hand ischemia (HAIDI = Hemodialysis Access Induced Distal Ischemia), while an abundant AVF flow may lead to the development of left ventricular hypertrophy, both with potentially severe consequences. These high-flow complications occur in approximately 20% of fistulae. Numerous studies have investigated alternative preoperative mapping tools and criteria for reduction of AVF related complications. However, current clinical use of these individual tools and parameters does not take into account their potential interplay at a systemic level. Therefore one might consider that multiple prognostic parameters within a single patient are likely more valuable to improve outcome and therefore it is obvious to tailor the type of AVF to the individual patient. A possible solution to deal with multiple independent prognostic factors is implementation of a predictive patient-specific computational tool that relates geometrical, mechanical and hemodynamical parameters by means of physical laws. As a result, the computational tool takes the complex interplay between different prognostic parameters into consideration and accounts for individual differences in anatomy, physiology, demography and hemodynamics. Such an innovative computational tool opens new opportunities. By predicting postoperative flow abovementioned deleterious events can possibly be prevented. High-flow (>1500ml/min) and low-flow (<600ml/min) vascular access can then be predicted and consequently be rejected and a more suitable AVF-configuration chosen.

Consequently, simulation of outcome after AVF creation is at hand. Recently, the feasibility of VA computational simulation has been investigated and proven in the ARCH FP7 ICT-224390 project (ARCH; patient-specific image-based computational modeling for improvement of short- and long- term outcome of vascular access in patients on hemodialysis therapy). Within this technological and clinical study, longitudinal collection of cardiovascular data was performed with the intention to develop, calibrate and validate patient-specific modelling tools for surgical planning and assistance in the management of complications arising from AVF creation. Given the difficult and heterogeneous patient population, the study protocol was designed in such way that pre- and postoperative imaging could be performed strictly, aiming at complete datasets of structural, functional and demographical data. Although the computational simulation model has been validated in a small patient group, larger randomized observational patient studies, aiming at evaluating the potential beneficial effect of the use of computational tools in reducing AVF-related clinical problems, are needed.

Being tested
AVF-simulation
Keywords
Arteriovenous fistulae (AVFs), Non-maturation, Computational simulation
Medical subject headings
Kidney Failure, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AVF-simulationDevice

    A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.

Study groups in NCT02453412
Study groupRoleWhat they receive
ControlNo interventionStandard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
SimulationExperimentalStandard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
Receives: Device: AVF-simulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occurence of non-maturation

    Yes/No

    A matured AVF has minimal flow of 500 mL/min and a minimal diameter of 4 mm by six weeks after AVF creation.

    Measured: 6 weeks postoperatively

Secondary outcomes (5)
  1. Occurence of high-flow complications

    Yes/No

    High flow complications considered are hemodialysis access induced distal ischemia (HAIDI) and heart failure. To classify for a high-flow complication, an AVF requires a flow reduction intervention within twelve weeks following creation. For this objective HAIDI and heart failure are not considered separately.

    Measured: 6 weeks postoperatively

  2. Primary patency rates

    Intervention free period from AVF construction until an intervention is used to maintain or regain a patent vascular access.

    Measured: 6 and 12 months

  3. Agreement between predicted and measured flow (mL/min)

    Correlation and/or Bland-Altman plot

    Measured: up to 6 weeks

  4. Usability of the computational tool

    Qualitative assessment of the perceived benefit by surgeons in surgery planning via interviews. The interview will focus on terms of user-friendliness, reporting speed, reliability of predictions, etc.

    Measured: 6 weeks

  5. Functional AVF

    AVF allows for cannulation with two needles and effective dialysis, with either dialysis blood flow >300mL/min without recirculation, or a measured kt/V ≥1.4 at the end of one of these sessions.

    Measured: >6 weeks (when AVF is matured)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 May 2015 (estimated)
  2. Study startMay 2015
  3. Primary completionJul 2018
  4. Study completionJun 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
236 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02453412
Sponsor's protocol ID
NT12.01
Other IDs
NL51610.068.14
Acronym
3S
Status last verified
Aug 2019
First submitted
12 May 2015
Last updated
22 Aug 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Publications

  • Zonnebeld N, Huberts W, van Loon MM, Delhaas T, Tordoir JH. Preoperative computer simulation for planning of vascular access surgery in hemodialysis patients. J Vasc Access. 2017 Mar 6;18(Suppl. 1):118-124. doi: 10.5301/jva.5000661. Epub 2017 Mar 5.

    PubMed 28297050

Questions about this trial

What is this clinical trial studying?

A study testing AVF-simulation in people with Kidney Failure, Chronic and Arteriovenous Fistulae, run by Maastricht University Medical Center at 9 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occurence of non-maturation (time frame: 6 weeks postoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02453412, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
3S Clinical Trial NCT02453412 | AzTrials